Neermann Joerg 4

What Happened
Joerg Neermann, a director of IMMUNIC, Inc. (IMUX), was granted 25,370 derivative securities reported as acquired on June 29, 2026. The Form 4 reports an acquisition price of $0.00, reflecting a grant of options (not an open-market purchase). This award is compensation-related rather than a cash purchase or sale.

Key Details

• Transaction date: 2026-06-29 (reported same day). Report filed: 2026-06-29 (timely).
• Reported transaction: Grant/award (derivative) of 25,370 shares @ $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote highlights:
  • F1: These are options to purchase common stock that were conditionally approved by the Board on March 27, 2026 and became effective after stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan at the June 29, 2026 Annual Meeting.
  • F2: The option award was fully vested as of March 27, 2026.
• Filing timeliness: No late filing indicated.

Context
This transaction is a grant of options (derivative securities). Options represent the right to buy shares in the future; they do not create immediate cash proceeds for the insider unless and until exercised and any resulting shares sold. Because the award was approved by both the Board and stockholders and was already fully vested, Neermann can exercise these rights according to the plan terms—exercise (and any subsequent sale) would be reported separately. Awards and grants are common executive/director compensation and are different from open-market purchases or insider sales.